Press release: dupixent approved in the us as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the us as the only targeted medicine to treat patients with bullous pemphigoid approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with bp bp is a chronic, debilitating, and relapsing rare skin disease affecting approximately 27,000 adults in the us whose disease is uncontrolled by systemic corticosteroids dupixent is now approved in the us to treat eight distinct diseases with underlying type 2 inflammation, including diseases of the skin, gut, and respiratory system that affect a broad range of patients, from infants to elderly people paris and tarrytown, ny, june 20, 2025. the us food and drug administration (fda) has approved dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid (bp).
REGN Ratings Summary
REGN Quant Ranking